

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING**Product Identifier****Material Name:** Risedronate Sodium Delayed-Release Tablets (Greenstone LLC)**Trade Name:** Not applicable**Chemical Family:** Bisphosphonate**Relevant Identified Uses of the Substance or Mixture and Uses Advised Against****Intended Use:** Pharmaceutical product**Details of the Supplier of the Safety Data Sheet**Greenstone LLC
100 Route 206 North
Peapack, NJ 07977
800-435-7095**Emergency telephone number:**
CHEMTREC (24 hours): 1-800-424-9300**2. HAZARDS IDENTIFICATION****Classification of the Substance or Mixture****GHS - Classification**

Reproductive Toxicity: Category 1B

Label Elements**Signal Word:** Danger**Hazard Statements:** H360FD - May damage fertility. May damage the unborn child.**Precautionary Statements:**P201 - Obtain special instructions before use
P202 - Do not handle until all safety precautions have been read and understood
P281 - Use personal protective equipment as required
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations**Other Hazards**

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

SAFETY DATA SHEET

Material Name: Risedronate Sodium Delayed-Release Tablets
(Greenstone LLC)
Revision date: 06-Mar-2018

Page 2 of 11

Version: 1.0

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Risedronate sodium	115436-72-1	Not Listed	Acute Tox. 4 (H302) Repr.1B (H360FD)	35 mg***
Talc (non-asbestiform)	14807-96-6	238-877-9	Not Listed	*
Microcrystalline cellulose	9004-34-6	232-674-9	Not Listed	*
Magnesium Stearate	557-04-0	209-150-3	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Methacrylic acid copolymer	25086-15-1	Not Listed	Not Listed	*
Ferric oxide yellow	51274-00-1	257-098-5	Not Listed	*
Sodium starch glycolate	9063-38-1	Not Listed	Not Listed	*
Stearic acid	57-11-4	200-313-4	Not Listed	*
Triethyl Citrate	77-93-0	201-070-7	Not Listed	*
Simethicone	8050-81-5	Not Listed	Not Listed	*
Polysorbate 80	9005-65-6	Not Listed	Not Listed	*
Edetate disodium	139-33-3	205-358-3	Not Listed	*

Additional Information:

* Proprietary

*** per tablet/capsule/lozenge/suppository

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

SAFETY DATA SHEET

Material Name: Risedronate Sodium Delayed-Release Tablets
(Greenstone LLC)
Revision date: 06-Mar-2018

Page 3 of 11

Version: 1.0

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO₂, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Cleanup operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical product

SAFETY DATA SHEET

Material Name: Risedronate Sodium Delayed-Release Tablets
(Greenstone LLC)
Revision date: 06-Mar-2018

Page 4 of 11

Version: 1.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Talc (non-asbestiform)

ACGIH Threshold Limit Value (TWA)	2 mg/m ³
Australia TWA	2.5 mg/m ³
Austria OEL - MAKs	2 mg/m ³
Belgium OEL - TWA	2 mg/m ³
Bulgaria OEL - TWA	1.0 fiber/cm ³
	6.0 mg/m ³
	3.0 mg/m ³
Czech Republic OEL - TWA	2.0 mg/m ³
Denmark OEL - TWA	0.3 fiber/cm ³
Finland OEL - TWA	0.5 fiber/cm ³
Greece OEL - TWA	10 mg/m ³
	2 mg/m ³
Hungary OEL - TWA	2 mg/m ³
Ireland OEL - TWAs	10 mg/m ³
	0.8 mg/m ³
Lithuania OEL - TWA	2 mg/m ³
	1 mg/m ³
Netherlands OEL - TWA	0.25 mg/m ³
OSHA - Final PELs - Table Z-3 Mineral D:	20 mppcf
Poland OEL - TWA	4.0 mg/m ³
	1.0 mg/m ³
Portugal OEL - TWA	2 mg/m ³
Romania OEL - TWA	2 mg/m ³
Slovakia OEL - TWA	2 mg/m ³
	10 mg/m ³
Slovenia OEL - TWA	2 mg/m ³
Spain OEL - TWA	2 mg/m ³
Sweden OEL - TWAs	2 mg/m ³
	1 mg/m ³

Microcrystalline cellulose

ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Australia TWA	10 mg/m ³
Belgium OEL - TWA	10 mg/m ³
Estonia OEL - TWA	10 mg/m ³
France OEL - TWA	10 mg/m ³
Ireland OEL - TWAs	10 mg/m ³
	4 mg/m ³
Latvia OEL - TWA	2 mg/m ³
OSHA - Final PELs - TWAs:	15 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Romania OEL - TWA	10 mg/m ³
Spain OEL - TWA	10 mg/m ³

Magnesium Stearate

Lithuania OEL - TWA	5 mg/m ³
Sweden OEL - TWAs	5 mg/m ³

SAFETY DATA SHEET

Material Name: Risedronate Sodium Delayed-Release Tablets
(Greenstone LLC)
Revision date: 06-Mar-2018

Page 5 of 11

Version: 1.0

Manufacturer OEB Statement:

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

Simethicone

Manufacturer OEB:

OEB1 (control exposure to the range of >1000ug/m³ to < 3000ug/m³)

Exposure Controls

Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

Hands:

Impervious disposable gloves (e.g. Nitrile, etc.) (double recommended) if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

Eyes:

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

Skin:

Impervious disposable protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

Respiratory protection:

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a full mask, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.)

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:

Tablets

Color:

No data available.

Odor:

No data available.

Odor Threshold:

No data available.

Molecular Formula:

Mixture

Molecular Weight:

Mixture

Solvent Solubility:

No data available

Water Solubility:

No data available

pH:

No data available.

Melting/Freezing Point (°C):

No data available

Boiling Point (°C):

No data available.

Partition Coefficient: (Method, pH, Endpoint, Value)

Edetate disodium

No data available

Ferric oxide yellow

No data available

Magnesium Stearate

No data available

Methacrylic acid copolymer

No data available

Simethicone

SAFETY DATA SHEET

Material Name: Risedronate Sodium Delayed-Release Tablets
(Greenstone LLC)
Revision date: 06-Mar-2018

Page 6 of 11

Version: 1.0

9. PHYSICAL AND CHEMICAL PROPERTIES

No data available

Sodium starch glycolate

No data available

Stearic acid

No data available

Triethyl Citrate

No data available

Polysorbate 80

No data available

Microcrystalline cellulose

No data available

Talc (non-asbestiform)

No data available

Risedronate sodium

No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available

Vapor Pressure (kPa): No data available

Vapor Density (g/ml): No data available

Relative Density: No data available

Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C): No data available

Flammability (Solids): No data available

Flash Point (Liquid) (°C): No data available

Upper Explosive Limits (Liquid) (% by Vol.): No data available

Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

Possibility of Hazardous Reactions

Oxidizing Properties: No data available

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Short Term: Accidental ingestion may cause effects similar to those seen in clinical use.

Known Clinical Effects: Common adverse effects include bone pain, back pain, abdominal pain, diarrhea, hypersensitivity reactions, and upset stomach.

Acute Toxicity: (Species, Route, End Point, Dose)

SAFETY DATA SHEET

Material Name: Risedronate Sodium Delayed-Release Tablets
(Greenstone LLC)
Revision date: 06-Mar-2018

Page 7 of 11

Version: 1.0

11. TOXICOLOGICAL INFORMATION

Edetate disodium

Rat Oral LD50 2000-2200 mg/kg

Stearic acid

Rat Oral LD50 > 4640 mg/kg

Rabbit Dermal LD50 > 5000mg/kg

Polysorbate 80

Rat Oral LD50 25 g/kg

Microcrystalline cellulose

Rat Oral LD50 > 5000 mg/kg

Rabbit Dermal LD50 > 2000 mg/kg

Talc (non-asbestiform)

Rat Oral LD50 > 1600 mg/kg

Risedronate sodium

Rat (M) Oral LD50 1703 mg/kg

Rat (F) Oral LD50 903mg/kg

Acute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Stearic acid

Skin Irritation Rabbit Moderate

Eye Irritation Rabbit Mild

Microcrystalline cellulose

Skin Irritation Rabbit Non-irritating

Eye Irritation Rabbit Non-irritating

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Magnesium Stearate

13 Week(s) Rat Oral 1092 g/kg LOAEL Liver

Stearic acid

30 Week(s) Rat Oral 300 ppm LOAEL Adipose tissue

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Risedronate sodium

Embryo / Fetal Development Rat Oral 7 mg/kg/day LOAEL Teratogenic

Reproductive & Fertility Rat Oral 7 mg/kg/day LOAEL Reproductive toxicity

SAFETY DATA SHEET

Material Name: Risedronate Sodium Delayed-Release Tablets
(Greenstone LLC)
Revision date: 06-Mar-2018

Page 8 of 11

Version: 1.0

11. TOXICOLOGICAL INFORMATION

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Stearic acid

In Vitro Bacterial Mutagenicity (Ames) *Salmonella* Negative
Unscheduled DNA Synthesis *E. coli* Negative

Risedronate sodium

In Vitro Bacterial Mutagenicity (Ames) *Salmonella*, *E. coli* Negative
In Vitro Mammalian Cell Mutagenicity Chinese Hamster Ovary (CHO) cells Negative
In Vitro Unscheduled DNA Synthesis Rat Hepatocyte Negative
In Vivo Chromosome Aberration Rat Bone Marrow Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Stearic acid

26 Week(s) Rat Subcutaneous 0.5 mg/kg/week NOEL Not carcinogenic
52 Week(s) Mouse Subcutaneous 0.05 mg/kg/week LOAEL Tumors

Risedronate sodium

104 Week(s) Rat Oral 24 mg/kg/day NOEL Not carcinogenic
80 Week(s) Mouse Oral 32 mg/kg/day NOEL Not carcinogenic

Carcinogen Status:

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

Talc (non-asbestiform)

IARC: Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview:

Environmental properties have not been investigated. Releases to the environment should be avoided.

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Risedronate sodium

Fish EC50 96 Hours 381 mg/L
Daphnia magna (Water Flea) EC50 48 Hours 184 mg/L

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

SAFETY DATA SHEET

Material Name: Risedronate Sodium Delayed-Release Tablets
(Greenstone LLC)
Revision date: 06-Mar-2018

Page 9 of 11

Version: 1.0

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications

WHMIS hazard class:

None required

Risedronate sodium

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

Talc (non-asbestiform)

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	238-877-9

Methacrylic acid copolymer

CERCLA/SARA 313 Emission reporting	Not Listed
------------------------------------	------------

SAFETY DATA SHEET

Material Name: Risedronate Sodium Delayed-Release Tablets
 (Greenstone LLC)
 Revision date: 06-Mar-2018

Page 10 of 11

Version: 1.0

15. REGULATORY INFORMATION

California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed
Ferric oxide yellow	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	257-098-5
Sodium starch glycolate	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed
Stearic acid	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	200-313-4
Triethyl Citrate	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	201-070-7
Simethicone	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed
Microcrystalline cellulose	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	232-674-9
Polysorbate 80	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present

SAFETY DATA SHEET

Material Name: Risedronate Sodium Delayed-Release Tablets
(Greenstone LLC)
Revision date: 06-Mar-2018

Page 11 of 11

Version: 1.0

15. REGULATORY INFORMATION

EU EINECS/ELINCS List	Not Listed
-----------------------	------------

Edetate disodium

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	205-358-3

Magnesium Stearate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	209-150-3

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed
Reproductive toxicity-Cat.1B; H360FD - May damage fertility. May damage the unborn child.

Data Sources: Publicly available toxicity information. Safety data sheets for individual ingredients.

Reasons for Revision: New data sheet.

Revision date: 06-Mar-2018
Product Stewardship Hazard Communication

Prepared by: Global Environment, Health, and Safety Operations

It is believed that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without a warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time

End of Safety Data Sheet